# Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

> **NCT06452537** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Tianjin Medical University General Hospital** · enrollment: 102 (estimated)

## Conditions studied

- Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06452537
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-09
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06452537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06452537, "Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06452537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*